Microplastics detected in cirrhotic liver tissue.
Level 4 - case-series / case-control
Small proof-of-concept case series with control tissue comparisons
PubMed 35835713 · doi:10.1016/j.ebiom.2022.104147
What was done
In a proof-of-concept case series in Germany, investigators analyzed 17 tissue samples (11 liver, 3 kidney, and 3 spleen) from 6 patients with liver cirrhosis and 5 individuals without liver disease. Tissues were processed via chemical digestion, Nile red staining, fluorescent microscopy, and Raman spectroscopy to detect, measure, and identify microplastic particles ranging from 4 to 30 µm in size.
What was found
All liver, kidney, and spleen samples from individuals without liver disease tested negative for microplastics above the limit of detection. In contrast, cirrhotic liver tissues tested positive, exhibiting significantly higher microplastic concentrations than non-cirrhotic controls and containing six distinct microplastic polymers between 4 and 30 µm in size (specific numeric concentrations were not reported in the abstract).
Why it matters
This provides initial proof-of-concept evidence that environmental microplastics can deposit and persist in diseased human liver tissue, highlighting a potential link between microplastic exposure and hepatic disease.
Limits
The study is constrained by a very small sample size (6 cirrhotic patients and 5 controls), a limited tissue panel, and an exploratory cross-sectional design that cannot determine whether microplastic accumulation contributes to the pathogenesis of liver fibrosis or is simply a consequence of cirrhosis and altered portal hemodynamics.
Cited by
- supports Liver tissue from patients with cirrhosis contains significantly higher levels of microplastics than healthy liver tissue.